News >

Expanding the Utility of Novel Combination Regimens in CLL

Caroline Seymour
Published: Friday, May 17, 2019

Danielle Brander, MD

Danielle Brander, MD

Although potent in and of themselves, ibrutinib (Imbruvica) and venetoclax (Venclexta), are showing enhanced safety profiles, time-limited administration, and patient scope when used in combination for the treatment of patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL), explained Danielle M. Brander, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication